id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2022-P-0585-0005,FDA,FDA-2022-P-0585,"Response Letter from FDA CDER to Odin Pharmaceuticals, LLC",Other,Letter(s),2022-12-09T05:00:00Z,2022,12,2022-12-09T05:00:00Z,,2022-12-09T16:59:07Z,,0,0,0900006485525f80
FDA-2022-P-0585-0004,FDA,FDA-2022-P-0585,"Determination That NORFLEX (Orphenadrine Citrate) Injection, 30 Milligrams/Milliliter, and NORFLEX (Orphenadrine Citrate) Extended-
Release Tablet, 100 Milligrams, Were Not Withdrawn From Sale for Reasons
of Safety or Effectiveness",Notice,Determinations,2022-12-08T05:00:00Z,2022,12,2022-12-08T05:00:00Z,,2022-12-08T16:06:44Z,2022-26663,0,0,0900006485524ea2
FDA-2022-P-0585-0003,FDA,FDA-2022-P-0585,"Interim response from FDA CDER to Odin Pharmaceuticals, LLC",Other,Response(s),2022-10-07T04:00:00Z,2022,10,2022-10-07T04:00:00Z,,2022-10-07T20:46:23Z,,0,0,09000064853d704d
FDA-2022-P-0585-0001,FDA,FDA-2022-P-0585,"Citizen Petition from Odin Pharmaceuticals, LLC",Other,Citizen Petition,2022-04-13T04:00:00Z,2022,4,2022-04-13T04:00:00Z,,2022-12-08T19:00:49Z,,0,0,09000064850156b8
FDA-2022-P-0585-0002,FDA,FDA-2022-P-0585,"Acknowledgment Letter from FDA DMS to Odin Pharmaceuticals, LLC",Other,Acknowledgement Letter/Receipt,2022-04-13T04:00:00Z,2022,4,2022-04-13T04:00:00Z,,2022-04-13T15:12:08Z,,0,0,09000064850156ba